At the Weizmann Institute of Science in Rehovot, Israel, Prof. Ziv Shulman's team has discovered something that cancer immunologists had long suspected but never proven: the body's own immune memory can recognize and fight cancer from within. In tissue samples from eleven ovarian cancer patients, researchers led by Dr. Nachum Nathan found memory B cells—the immune system's trained sentries—circulating near tumors and producing antibodies specifically designed to attack cancer. More than a third of these antibodies bound strongly to ovarian cancer cells, suggesting the immune system had already begun mounting a targeted, long-term defense.
What makes this discovery significant is that cancer vaccines and immunotherapies have historically struggled to generate lasting immune memory against tumors. The immune system excels at remembering viruses and bacteria—that's why childhood vaccinations protect us for decades—but cancer cells are treacherous: they originate from the body's own tissue, making it hard for the immune system to distinguish them from healthy cells. Yet here, in tissue samples collected in collaboration with Prof. Ram Eitan and Dr. Oded Raban from Rabin Medical Center, the researchers found something unexpected. The lymph nodes adjacent to tumors weren't mounting an active immune assault; instead, they harbored dormant memory B cells whose genetic blueprints coded for cancer-fighting antibodies. When Shulman's team sequenced the genetic "recipe" for these antibodies and produced them artificially in the laboratory, the results were striking.
"We were amazed to find that more than a third of these antibodies bound strongly to ovarian cancer cells," Shulman recalls. The team worried at first that they had discovered something less remarkable—antibodies simply attacking any human cell indiscriminately—but the evidence pointed elsewhere. These antibodies bound far less effectively to healthy, non-cancerous cell types. The memory cells had evolved into a precision weapon against ovarian cancer specifically.
What unfolds across tissue samples is a portrait of immune vigilance. While the memory cells rested in nearby lymph nodes, the researchers discovered that related B cells were actively proliferating within the tumor itself, belonging to the same genetic clones as their dormant counterparts. This suggests a coordinated long-term immune campaign: memory B cells migrate from lymph nodes to the tumor, re-engage in "training camps" called germinal centers within cancerous tissue, and generate new waves of antibodies against cancer cells. It's an immune response that cancer had somehow failed to fully suppress.
The findings, published today in Immunity, study the most common form of ovarian cancer, known as HGSOC, and apply specifically to those eleven patients. But the implications ripple outward. If memory B cells can indeed provide lasting immunological protection against ovarian cancer, the blueprint for developing cancer vaccines and therapies based on immune memory becomes clearer. Rather than teaching the immune system to recognize cancer from scratch, clinicians might harness and amplify the memory cells that are already doing the job. Dr. Nachum Nathan frames it plainly: memory cells that migrate from lymph nodes to tumors and generate effective immune responses "participate in a long-term immune battle against cancer—a discovery that may advance the development of innovative treatments for ovarian cancer and other malignancies." That battle, it turns out, has been waging quietly all along.